Quarterly report pursuant to Section 13 or 15(d)

Equity (Details)

v3.8.0.1
Equity (Details)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 15, 2017
USD ($)
Jul. 29, 2017
warrant
$ / shares
shares
May 15, 2017
USD ($)
Mar. 24, 2017
shares
Feb. 21, 2017
USD ($)
Feb. 14, 2017
USD ($)
$ / shares
shares
Jan. 13, 2017
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Aug. 31, 2017
$ / shares
Jul. 31, 2017
$ / shares
Jan. 31, 2017
USD ($)
$ / shares
shares
Aug. 31, 2017
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Feb. 09, 2017
$ / shares
Dec. 31, 2016
USD ($)
shares
May 02, 2016
shares
Apr. 22, 2016
shares
Class of Stock [Line Items]                                      
Shares authorized                                   80,000,000  
Preferred stock authorized (in shares) 5,000,000               5,000,000         5,000,000 5,000,000   5,000,000 5,000,000  
Common stock authorized (in shares) 75,000,000               75,000,000         75,000,000 75,000,000   75,000,000 75,000,000  
Preferred stock, shares issued 0               0         0 0   0    
Accounts payable and accrued liabilities | $ $ 1,089,000               $ 1,089,000         $ 1,089,000 $ 1,089,000   $ 1,069,000    
Public offering price per share (in dollars per share) | $ / shares $ 1.35               $ 1.35         $ 1.35 $ 1.35        
Net proceeds from IPO | $       $ 1,240,000                              
Proceeds from issuance of common stock | $                 $ 400,000                    
Additional shares available for purchase                             160,000        
Exercise price (in dollars per share) | $ / shares                             $ 2.14        
Expected dividend payments | $                             $ 0        
Estimated forfeiture rate 0.00%               0.00%         0.00% 0.00%        
Share-based compensation expense | $                           $ 200,000 $ 500,000        
Unrecognized compensation cost, net of estimated forfeitures, related to the Company's non-vested equity awards | $ $ 1,600,000               $ 1,600,000         $ 1,600,000 $ 1,600,000        
Weighted average period of expected recognition of compensation cost (in years)                             3 years 4 months 1 day        
Maximum                                      
Class of Stock [Line Items]                                      
Public offering price per share (in dollars per share) | $ / shares                               $ 1.50      
Discount range used in option-pricing model (percentage)                             2.24%        
Expected range of lives used in option-pricing model (in years)                             6 years 3 months        
Volatility range used in option-pricing model                             89.11%        
Minimum                                      
Class of Stock [Line Items]                                      
Public offering price per share (in dollars per share) | $ / shares                               $ 1.35      
Discount range used in option-pricing model (percentage)                             1.30%        
Expected range of lives used in option-pricing model (in years)                             5 years        
Volatility range used in option-pricing model                             70.18%        
Former Science Advisory Board                                      
Class of Stock [Line Items]                                      
Stock issued for consulting services (in shares)               79,167                      
Gain on settlement of liability | $           $ 150,000                          
Accounts payable and accrued liabilities | $                                 $ 240,000    
IPO                                      
Class of Stock [Line Items]                                      
Number of units issued (in shares)             3,923,923                        
Public offering price per share (in dollars per share) | $ / shares             $ 1.35                        
Net proceeds from IPO | $             $ 4,500,000                        
At Market Issuance Sales Agreement                                      
Class of Stock [Line Items]                                      
Proceeds from issuance of common stock | $                             $ 400,000        
Commissions paid, percentage of gross proceeds   3.00%                                  
2015 Stock Plan                                      
Class of Stock [Line Items]                                      
Total number of underlying shares of common stock available under 2015 Stock Plan                                     2,500,000
Science Advisory Board                                      
Class of Stock [Line Items]                                      
Additional shares available for purchase                       20,000              
Exercise price (in dollars per share) | $ / shares                       $ 2.31              
Term of awards                       10 years              
Vesting period                       4 years              
Aggregate fair value of options granted | $                       $ 35,196              
Board and Management                                      
Class of Stock [Line Items]                                      
Additional shares available for purchase                         140,000            
Exercise price (in dollars per share) | $ / shares                   $ 2.88 $ 1.87                
Term of awards                         10 years            
Vesting period                         4 years            
Aggregate fair value of options granted | $                             269,592        
The Warrants                                      
Class of Stock [Line Items]                                      
Period of agreement     12 months                                
Number of warrants issued | warrant     2                                
Vesting period     12 months                                
Expiration period     5 years                                
Stock compensation expense | $                             $ 63,000        
GSK Consulting Agreement Warrant One                                      
Class of Stock [Line Items]                                      
Class of warrants, aggregate amounts (in shares)     100,000                                
Exercise price per warrant (in dollars per share) | $ / shares     $ 2.41                                
GSK Consulting Agreement Warrant Two                                      
Class of Stock [Line Items]                                      
Class of warrants, aggregate amounts (in shares)     50,000                                
Exercise price per warrant (in dollars per share) | $ / shares     $ 3.00                                
Common Stock                                      
Class of Stock [Line Items]                                      
Stock issued for consulting services (in shares)                             79,167        
New stock issuance (in shares)         298,150       154,121                    
Common Stock | Maximum                                      
Class of Stock [Line Items]                                      
Public offering price per share (in dollars per share) | $ / shares $ 2.71               $ 2.71         $ 2.71 $ 2.71        
Common Stock | Minimum                                      
Class of Stock [Line Items]                                      
Public offering price per share (in dollars per share) | $ / shares $ 2.52               $ 2.52         $ 2.52 $ 2.52        
Common Stock | At Market Issuance Sales Agreement                                      
Class of Stock [Line Items]                                      
Number of shares sold 154,121                                    
Common Stock | Agents | At Market Issuance Sales Agreement | Maximum                                      
Class of Stock [Line Items]                                      
Aggregate sales price | $   $ 13,000,000